header logo image


Page 36«..1020..35363738..5060..»

Archive for the ‘Biotechnology’ Category

To fight the coronavirus, labs are printing its genome – The Verge

Tuesday, February 11th, 2020

Advancements in genetic technology are making it easier, faster, and less expensive for public health experts to understand how the new coronavirus spreads. Time is of the essence for the people on the frontlines of this viral outbreak as the virus has already sickened more than 40,000 people and killed 910.

Researchers got an early win in January. It only took two weeks after public health officials reported the virus to the World Health Organization (WHO) for scientists to isolate the virus and figure out the full sequence of its genetic material. As soon as that sequence was public, biotechnology companies started creating synthetic copies of the virus that could be used in research.

This all happened faster than it ever has before. During the SARS outbreak in 2002, it was months before the viral genome was sequenced and longer still before it was remade in the lab. Speed is important because the outbreak is unlike anything public health experts have seen before. Since the start of February, over 20,000 new people developed confirmed cases of the viral infection. Despite efforts to stop the spread of the virus, some experts worry that it wont be possible.

Genetic synthesis is also much cheaper than it was two decades ago. Then, it cost $10 to create a synthetic copy of one single nucleotide, the building block of genetic material. Now, its under 10 cents. The new coronavirus gene is around 30,000 nucleotides long, so that reduction in price makes a big difference in how many copies scientists can make.

With genetic sequences and synthetic copies, experts were able to quickly develop diagnostic tests for the virus. Last week, just over a month after the virus was reported, the Centers for Disease Control and Prevention (CDC) started shipping testing kits it developed to labs in the US and internationally. It was also able to start creating vaccines. Dozens are under development at pharmaceutical companies, and Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases, says that one vaccine candidate will enter clinical trials within three months.

In our latest Verge Science video, we take a look at the genetic processes that made these developments possible and how theyre helping in the fight against the coronavirus epidemic.

Correction: An earlier version of this story referred to the coronavirus genetic material as DNA. The coronavirus is an RNA virus.

Original post:
To fight the coronavirus, labs are printing its genome - The Verge

Read More...

The Global Marine Biotechnology Market is expected to grow by USD 2.5 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -…

Tuesday, February 11th, 2020

Global Marine Biotechnology Market 2020-2024 The analyst has been monitoring the global marine biotechnology market and it is poised to grow by USD 2. 5 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period.

New York, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Marine Biotechnology Market 2020-2024" - https://www.reportlinker.com/p05273066/?utm_source=GNW Our reports on global marine biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in demand for biofuel. In addition, increasing application of seaweeds is anticipated to boost the growth of the global marine biotechnology market as well.

Market Segmentation The global marine biotechnology market is segmented as below:

Application Healthcare Products Energy And Environment Management Products Food And Cosmetics Products Geographic segmentation APAC Europe MEA North America South America

Key Trends for global marine biotechnology market growth This study identifies increasing application of seaweeds as the prime reasons driving the global marine biotechnology market growth during the next few years.

Prominent vendors in global marine biotechnology market We provide a detailed analysis of around 25 vendors operating in the global marine biotechnology market , including some of the vendors such as Aker BioMarine AS, BASF SE, CP Kelco, Cyanotech Corp., KD Pharma Group, LAir Liquide SA, Lonza Group Ltd., Marinomed Biotech AG, PharmaMar SA and Sea Run Holdings Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Read the full report: https://www.reportlinker.com/p05273066/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original post:
The Global Marine Biotechnology Market is expected to grow by USD 2.5 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -...

Read More...

Agricultural Biotechnology Market 2020 Growing Technology Trends, Demand and Business Opportunities by 2025 – Chronicle 99

Tuesday, February 11th, 2020

Agricultural Biotechnology Market report offers the clients with a unique opportunity that can drive them to higher levels of success and to great achievement. The Agricultural Biotechnology Market report is created for clients by our analysts for resulting in best future planning of their business or start-up. The Agricultural Biotechnology Market report consists of the revenues, retail and wholesale, royalty, profits, incentives, and other factors, of the major players. This report proves to be best for a business plan and intends to maximize the rewards for effort and provides substantial and ongoing income. Along with that this report also offers the product sales done by the contenders of the Agricultural Biotechnology Market.

Get Research Insights @ https://www.adroitmarketresearch.com/contacts/request-sample/113

The use of biotechnological sciences is prevalent in many sectors. The agricultural biotechnology market can be categorized into two main segments: transgenic seeds and crop protection techniques. The application of biotechnology in the agricultural field helps in developing plants, animals and other living beings, by modifying them genetically, which can increase the productivity of crops (transgenic or genetically modified). It can also protect crops from destructive diseases. It is an innovative technology which has proven to be cost effective for the production of crops. With the rising population across the world, clearly theres a requirement for more food production, which is mostly dependent on farming.

There is a gap between the demand of food grains and their supply. This method of crop production results in more varieties of crops, with a higher yield, which is high in nutritional value and resistant to pests, giving a longer shelf life to the products. Some of the major crops being produced by genetic modification are soybean, corn, and potato. Apart from food consumption, this technology is also used to meet the demand for biofuels. Seed manufacturing companies like Monsanto (US), DuPont (US), Sakata (Japan) etc. are major producers of corn, which is used as biofuel and in the production of bio-plastic. The rising per capita income and decreasing area of cultivatable land are other factors promoting the growth of the global agricultural biotechnology industry.

Get 10% Discount on this Report @ https://www.adroitmarketresearch.com/contacts/discount/113

North America dominated the production of genetically modified crops in 2015. There is more awareness and acceptance of this kind of crop production in American countries, along with supportive governmental laws and regulations. Major production companies are based in this region, which are heavily investing in the research and development of agricultural biotechnology. North America is expected to maintain its dominance throughout the forecast period and drive this market towards further growth. The Asia Pacific region is also witnessing a tremendous growth in the agricultural biotechnology market due to its rising population, and the demand for food and biotechnology based products.

This region is rapidly adapting modern techniques for farming. Genetically modified golden, pest resistant biotech wheat, and insect resistant biotech mustard are some of the crops that are being mass produced for consumption in this region. However, the European market is hesitant to the production of genetically modified crops. The European Union has developed and implemented a complex policy framework, since the 1990s, which has slowed down and limited the research and development of genetically modified crops. These regulations are likely to hinder the growth of the global agricultural biotechnology market in this region.

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry.

For Any Query on the Agricultural Biotechnology Market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

What to expect from the Agricultural Biotechnology Market report?

About Adroit Market Research:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Read the original:
Agricultural Biotechnology Market 2020 Growing Technology Trends, Demand and Business Opportunities by 2025 - Chronicle 99

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 – Jewish Life…

Tuesday, February 11th, 2020

The Nanoparticles in Biotechnology and Pharmaceuticals Market report 2020-2026 provides a comprehensive analysis of the current market for Smart Camera. It determines the market size of Nanoparticles in Biotechnology and Pharmaceuticals and also determines the factors that control market growth. The report begins with a basic overview of the Nanoparticles in Biotechnology and Pharmaceuticals industry and then goes into the Details of the Nanoparticles in Biotechnology and Pharmaceuticals market.

The Nanoparticles in Biotechnology and Pharmaceuticals market report provides detailed information on key factors, Opportunities, Challenges, industry trends and their impact on the market. The market report Nanoparticles in Biotechnology and Pharmaceuticals also includes company data and its operation. This report also contains information about the pricing strategy, brand strategy and target customer of the Nanoparticles in Biotechnology and Pharmaceuticals market. It also provides the distributors/dealer list offered by the company. This research report also deals with the main competition, the market development with forecast of the expected years and the expected growth rates. The main factors that drive and influence growth market data and analysis come from a combination of primary and secondary sources.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=JLN&utm_medium=002

[Note: our free sample report provides a brief introduction to the table of contents, table of contents, list of tables and figures, competitive landscape and geographic segmentation, as well as innovations and future developments based on research methods.]

The top Manufacturer with company profile, sales volume, and product specifications, revenue (Million/Billion USD) and market share

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Insights

The competitive analysis serves as a bridge between manufacturers and other participants that are available on the Nanoparticles in Biotechnology and Pharmaceuticals Market. The report includes a comparative study of Top market players with company profiles of competitive companies, Nanoparticles in Biotechnology and Pharmaceuticals Market product innovations and cost structure, production sites and processes, sales details of past years and technologies used by them. The Nanoparticles in Biotechnology and Pharmaceuticals Market report also explains the main strategies of competitors, their SWOT analysis and how the competition will react to changes in marketing techniques. In this report, the best market research techniques were used to provide the latest knowledge about Nanoparticles in Biotechnology and Pharmaceuticals Market to competitors in the market.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Segmentation information

The report provides important insights into the various market segments presented to simplify the assessment of the global Nanoparticles in Biotechnology and Pharmaceuticals Market. These market segments are based on several relevant factors, including Nanoparticles in Biotechnology and Pharmaceuticals Market product type or services, end users or applications and regions. The report also includes a detailed analysis of the regional potential of the Nanoparticles in Biotechnology and Pharmaceuticals Market, which includes the difference between production values and demand volumes, as well as the presence of market participants and the growth of each Region over the given forecast period

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=JLN&utm_medium=002

Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Nanoparticles in Biotechnology and Pharmaceuticals markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Nanoparticles in Biotechnology and Pharmaceuticals industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Nanoparticles in Biotechnology and Pharmaceuticals industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Nanoparticles in Biotechnology and Pharmaceuticals industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Nanoparticles in Biotechnology and Pharmaceuticals industry.

Market Dynamics: The report offers deep insights into the dynamics of the Nanoparticles in Biotechnology and Pharmaceuticals industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Nanoparticles in Biotechnology and Pharmaceuticals industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Nanoparticles in Biotechnology and Pharmaceuticals industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Nanoparticles in Biotechnology and Pharmaceuticals industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Nanoparticles in Biotechnology and Pharmaceuticals industry.

What will you find out from the global Nanoparticles in Biotechnology and Pharmaceuticals Market Report?

The report contains statistical analyses of the current and future Status of the global Nanoparticles in Biotechnology and Pharmaceuticals Market with a forecast to 2026.The report contains detailed information on manufacturers, Nanoparticles in Biotechnology and Pharmaceuticals Market raw material suppliers and buyers with their trade outlook for 2020-2026.The report informs you about the most important drivers, technologies and Trends that will shape the global Nanoparticles in Biotechnology and Pharmaceuticals Market in the near future.The report added an exclusive market segmentation, broken down by Product Type, Nanoparticles in Biotechnology and Pharmaceuticals Market end user and Region.The strategic perspectives on Nanoparticles in Biotechnology and Pharmaceuticals Market Dynamics, current production process and applications.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=JLN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

More:
Nanoparticles in Biotechnology and Pharmaceuticals Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 - Jewish Life...

Read More...

Improving food production with agricultural technology and plant biotechnology – The John Innes Centre

Tuesday, February 11th, 2020

Learn how to address challenges in growing, harvesting, and processingfood and build your knowledge of food production challenges and technology with this FutureLearn online course for 16-19 year olds studyingbiology.

Are you inspired to join the next generation of scientists and tackle challenges in food security?

On this course, you will get access to innovative research solutions that address some of the biggest issues in food, agriculture, and plant biotechnology.

You will become more familiar with the journey plants take, from crops in the field to food on your plate. You will explore the importance of scientific research in food security and discover the new technologies that are transforming agriculture.

The course starts on 2 March 2020 and mentors will be online to interact with learners until 22 March 2020. Participants will be able to join the course up until 4 May 2020.

By the end of the course, youll be able to

See the original post here:
Improving food production with agricultural technology and plant biotechnology - The John Innes Centre

Read More...

Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines -…

Tuesday, February 11th, 2020

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation(www.generex.com) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00AM Eastern time.

Agenda

On the call, Mr. Moscato and his team will provide an overview of how NuGenerex Immuno-Oncologys Ii-Key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus and a review of work with development partners & government agencies to implement Ii-Key peptide vaccines to implement a rapid response vaccination strategy that can provide immunity to the 2019-nCOV and Avian influenza (Bird Flu). Additionally, management will discuss the opportunity for NuGenerex Diagnostics to develop a rapid test for 2019-nCOV in respiratory and blood samples using its proprietary NGDx Express 2 rapid diagnostic technology.

Mr. Moscato will also provide details on a variety of upcoming corporate actions, including closing of the ALTuCELL acquisition, the S1 funding, an update on the Nasdaq listing process, the public spinout of NGIO directly to Nasdaq, and an overview of plans to initiate the Arizona operations and partnerships with physician groups to establish an end-to-end, comprehensive solution for managing patients with diabetes.

Mr. Moscato said, As announced last week, we will finally pay our stock dividend to our valuable shareholders on February 24th. This dividend fulfills the promises we made when we took over as management three years ago to reward shareholders when we advance our strategy to rebuild Generex. Once the dividend is paid, we can price the S1 and take in our funding, which will enable us to execute on our go forward plans. The S1 funding will allow us to close ALTuCELL and initiate clinical trials of their cell encapsulation technology for the treatment of Type I and Type II diabetes. Continuing our efforts in diabetes management, we plan to start our Arizona operations and begin the buildout of our multi-specialty, integrated care model for diabetes patients in collaboration with our physician partners at three major primary care and endocrinology practices under the banner of NuGenerex Health. Additionally, we have secured a surgery center as part of our integrated care model, which will advance our ultimate goal to set up the NuGenerex Health MSO and HMO in Arizona.

Mr. Moscato continued, With the impending S1 funding, we can fully fund the commercial operations of our subsidiaries with the sales, marketing, and operating budgets that our FDA cleared products deserve. We will expand the Excellagen sales force, and roll out two new product offerings from Olaregen, Dermacell and Olarex, which we expect to generate significant sales going forward. We are also excited about the launch of Excellagen Aesthetics in the aesthetic dermatology market. We will also expand the sales and marketing effort and build the inventory of MediSource Partners and Pantheon to focus on geographic expansion and revenue growth.

In addition to funding our revenue generating subsidiaries we will fund our clinical development stage subsidiaries, including Regentys, which will initiate the manufacturing and clinical supply of Extra-Cellular Matrix Hydrogel (ECMH) for the treatment of ulcerative colitis and inflammatory bowel diseases. We will continue to fund NuGenerex Immuno-Oncology and our ongoing Phase II clinical trial of AE37 peptide immunotherapeutic vaccine in combination with pembrolizumab (Mercks Keytruda) which is currently recruiting patients. We are excited that once the dividend is paid, we will be able to execute on all of our endeavors that will manifest into the enterprise we envisioned when we took over Generex with a promise to build shareholder value. Part of that strategy was to reclaim the value of our immunotherapy assets that include AE37 and the Ii-Key technology for cancer immunotherapy, and we are now positioned to realize that goal through the spin-out of NuGenerex immuno-Oncology (NGIO) as a separate public company on the Nasdaq.

Mr. Moscato concluded, The emergence of the coronavirus pandemic reminds us of the mid-2000s when Generex maintained a robust and successful research effort to make a rapid-response pandemic virus vaccine based on the Ii-Key technology that the company utilizes for our cancer immunotherapy program. A decade ago, Dr. Eric von Hofe, Chief Scientific Officer of NGIO and his team developed potential Ii-Key peptide vaccines for avian influenza (bird flu), swine flu, and SARS. Dr. von Hofe will discuss how Generex can revive the Ii-Key pandemic R&D program to fight the threat of the deadly 2019-nCOV pandemic, how our Ii-Key technology works to generate a protective immune system response, and how fast, easy and cost effective we can manufacture Ii-Key vaccines given our vast experience in the field. We also hope to provide an update on potential opportunities on which we have been working with Chinese entities and partners to deploy our Ii-Key peptide vaccine solution in China.

As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.

Dial-in instructions for the investor conference call will be announced prior to the meeting date.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato646-599-6222

Todd Falls1-800-391-6755 Extension 222investor@generex.com

Continue reading here:
Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines -...

Read More...

Is Trillium Therapeutics Inc (TRIL) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Tuesday, February 11th, 2020

Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Trillium Therapeutics Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 45 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trillium Therapeutics Inc (TRIL) stock is lower by -2.89% while the S&P 500 has risen 0.53% as of 10:02 AM on Tuesday, Feb 11. TRIL is down -$0.10 from the previous closing price of $3.57 on volume of 168,469 shares. Over the past year the S&P 500 has risen 24.35% while TRIL has risen 179.84%. TRIL earned $2.58 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.34.

To see the top 5 stocks in Biotechnology click here.

Visit link:
Is Trillium Therapeutics Inc (TRIL) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

Why Shares of Vir Biotechnology, Inc. (VIR) Are -4.85% Lower Today – Find News

Tuesday, February 11th, 2020

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the worst performers on the stock market today. At current price of $19.05, the shares have already lost -0.97 points (-4.85% lower) from its previous close of $20.02. Should you buy or avoid them? The stock sets an active trading volume day with a reported 105871 contracts so far this session. VIR shares had a relatively better volume day versus average trading capacity of 304.23 thousand shares, but with a 0.1 billion float and a -12.21% run over a week, its definitely worth keeping an eye on. The one year price forecast for VIR stock indicates that the average analyst price target is $26.33 per share. This means the stock has a potential increase of 38.22% from where the VIR share price has been trading recently.

Looking at the current readings for Vir Biotechnology, Inc., the two-week RSI stands at 51.22. This figure suggests that VIR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current VIR readings is similarly very revealing as it has a stochastic reading of 28.85% at this stage. This figure means that VIR share price today is being overbought.

Technical chart claims that Vir Biotechnology, Inc. (VIR) would settle between $20.82/share to $21.62/share level. However, if the stock price goes below the $19.26 mark, then the market for Vir Biotechnology, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $18.51 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -1.67. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at JP Morgan lowered their recommendation on shares of VIR from Overweight to Neutral in their opinion released on February 04. Robert W. Baird, analysts launched coverage of Vir Biotechnology, Inc. (NASDAQ:VIR) stock with a Neutral recommendation, according to their flash note issued to investors on November 14. Analysts at JP Morgan, made their first call for the equity with a Overweight recommendation, according to a research note that dated back to November 05.

VIR equity has an average rating of 2.2, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 3 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 3 analysts rated Vir Biotechnology, Inc. (NASDAQ:VIR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the companys stock.

Continue reading here:
Why Shares of Vir Biotechnology, Inc. (VIR) Are -4.85% Lower Today - Find News

Read More...

Reasons Why Long-term Faith on Puma Biotechnology, Inc. (PBYI) Could Pay Off Investors – The InvestChronicle

Tuesday, February 11th, 2020

Lets start up with the current stock price of Puma Biotechnology, Inc. (PBYI), which is $12.33 to be very precise. The Stock rose vividly during the last session to $12.9 after opening rate of $12.8 while the lowest price it went was recorded $12.13 before closing at $12.80.

Puma Biotechnology, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $43.90 on 03/18/19, with the lowest value was $6.26 for the same time period, recorded on 11/07/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Puma Biotechnology, Inc. shares are logging -71.91% during the 52-week period from high price, and 96.96% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $6.26 and $43.90.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.68 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Puma Biotechnology, Inc. (PBYI) recorded performance in the market was 40.91%, having the revenues showcasing 64.07% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 507.13M, as it employees total of 272 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.82, with a change in the price was noted +0.67. In a similar fashion, Puma Biotechnology, Inc. posted a movement of +5.75% for the period of last 100 days, recording 1,989,008 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for PBYI is recording 5.48 at the time of this writing. In addition, long term Debt to Equity ratio is set at 5.48.

Raw Stochastic average of Puma Biotechnology, Inc. in the period of last 50 days is set at 65.10%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 63.92%. In the last 20 days, the companys Stochastic %K was 71.35% and its Stochastic %D was recorded 80.67%.

Bearing in mind the latest performance of Puma Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 40.91%. Additionally, trading for the stock in the period of the last six months notably improved by 10.48%, alongside a downfall of -53.15% for the period of the last 12 months. The shares increased approximately by 22.59% in the 7-day charts and went up by 53.36% in the period of the last 30 days. Common stock shares were driven by 64.07% during last recorded quarter.

See the original post:
Reasons Why Long-term Faith on Puma Biotechnology, Inc. (PBYI) Could Pay Off Investors - The InvestChronicle

Read More...

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

Saturday, February 8th, 2020

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

Go here to read the rest:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Read More...

Researchers identify roots of childhood asthma – European Biotechnology

Saturday, February 8th, 2020

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Read More...

Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? – InvestorsObserver

Saturday, February 8th, 2020

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the article here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

Read More...

Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE – Simply Wall St

Saturday, February 8th, 2020

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, well use ROE to better understand Avecho Biotechnology Limited (ASX:AVE).

Over the last twelve months Avecho Biotechnology has recorded a ROE of 2.5%. One way to conceptualize this, is that for each A$1 of shareholders equity it has, the company made A$0.03 in profit.

Check out our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Avecho Biotechnology:

2.5% = AU$158k AU$6.2m (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders equity is to subtract the companys total liabilities from the total assets.

Return on Equity measures a companys profitability against the profit it has kept for the business (plus any capital injections). The return is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Avecho Biotechnology has a lower ROE than the average (7.7%) in the Pharmaceuticals industry.

That certainly isnt ideal. Wed prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Most companies need money from somewhere to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Avecho Biotechnology is free of net debt, which is a positive for shareholders. Without a doubt it has a fairly low ROE, but that isnt so bad when you consider it has no debt. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities.

Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt.

But when a business is high quality, the market often bids it up to a price that reflects this. It is important to consider other factors, such as future profit growth and how much investment is required going forward. Check the past profit growth by Avecho Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read this article:
Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE - Simply Wall St

Read More...

Here’s Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today – Motley Fool

Saturday, February 8th, 2020

What happened

Shares of Inovio Pharmaceuticals (NASDAQ:INO) and Vir Biotechnology (NASDAQ:VIR), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (NASDAQ:GILD) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

Image source: Getty Images.

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

Continue reading here:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today - Motley Fool

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts…

Saturday, February 8th, 2020

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

Read the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

Read More...

Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech News

Saturday, February 8th, 2020

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

Go here to read the rest:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

Read More...

Biotech stocks get a boost from coronavirus fears — but here’s why investors should be wary – Yahoo Finance

Saturday, February 8th, 2020

Pharmaceutical stocks, which have seen temporary spikes during the coronavirus crisis as investors bet on the possibility of a vaccine, may be getting ahead of themselves.

Markets are speculating that some products may prove instrumental in the fight against the deadly disease, which has infected thousands in China, left 200 dead and rattled global markets.

However, biotech experts say that buyers should certainly be wary of trying to trade on coronavirus fears, given that most companies lack an established track record or are simply trying to position themselves to benefit from public health crisis.

Theres two things that biotech companies, especially small ones, are always looking for: Attention and cash, Brad Loncar, a biotech investor, told Yahoo Finance on Friday.

And, sadly, a lot of them take advantage of situations...putting out a press release saying they are working on something and you see their stocks zoom, Loncar added.

To be sure, not all pharma companies are created equal. To fight the coronavirus, large cap companies like Johnson & Johnson (JNJ), AbbVie (ABBV) and Gilead Sciences (GILD) announced they were repurposing HIV, Ebola and Zika products that had been developed but are not on the market to create a vaccine. Separately, Roche is planning to disseminate testing kits for the virus.

Meanwhile, China and Hong Kongs biotech companies may hold more promise for finding a treatment or cure, amid a rise of domestic Chinese companies competing with U.S. or European brands.

A lot of people dont know theres a biotech boom happening in China today, according to Loncar, who manages a Chinese biotech exchange-traded fund. Its an example that China can rise to this call.

People wear face masks and walk at a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. People wear face masks as they walk through a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. According to the Taiwan Centers of Disease Control (CDC) Friday, the tenth case diagnosed with the new coronavirus has been confirmed in Taiwan. (AP Photo/Chiang Ying-ying)

Yet finding effective treatments and cures for the virus is easier said than done. It took five years for the first Ebola vaccine to hit the market, and the coronavirus vaccine is likely to follow the same pattern.

Barring a dramatic breakthrough, it means the sickness could rage for an extended period before a solution is found which means investors should be particularly careful about sinking money into biotech and pharma companies making big promises.

That includes stocks of smaller companies, which saw fleeting rallies last week on vaccine speculation. Inovio (INO), Moderna (MRNA), Novavax (NVAX), Meridian Biosciences (VIVO), Vir Biotechnology (VIR) and BioCryst (BCRX). Virtually all of them have pared or completely reversed the weeks initial gains.

Its important to know how big the potential universe for any vaccine is likely to be, Chris Meekins, a biotech analyst, told Yahoo Finance this week.

So companies that have a partnership with the government those would be areas that are better to invest in than companies that dont have government funding, because I dont believe theres a sustained investment, he added.

Robert W. Baird research analyst Brian Skorney told Yahoo Finance the companies who do end up making something are likely not to make any money either.

It is really unlikely that anyone is going to get paid for product that even does treat coronavirus, Skorney said. its not going to be something that companies are going to be able to generate a substantial profit, he said.

Read the original:
Biotech stocks get a boost from coronavirus fears -- but here's why investors should be wary - Yahoo Finance

Read More...

Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology – InvestorsObserver

Saturday, February 8th, 2020

Halozyme Therapeutics, Inc. (HALO) is near the top in its industry group according to InvestorsObserver. HALO gets an overall rating of 54. That means it scores higher than 54 percent of stocks. Halozyme Therapeutics, Inc. gets a 60 rank in the Biotechnology industry. Biotechnology is number 51 out of 148 industries.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $20.83 as of 10:15 AM on Wednesday, Feb 5, a rise of $1.53, or 7.9% from the previous closing price of $19.30. The stock has traded between $20.06 and $21.28 so far today. Volume today is low. So far 663,847 shares have traded compared to average volume of 1,434,881 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology - InvestorsObserver

Read More...

Where Is The Biotech Market Heading? – CIO Applications

Saturday, February 8th, 2020

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

Originally posted here:
Where Is The Biotech Market Heading? - CIO Applications

Read More...

Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 – TheLoop21

Saturday, February 8th, 2020

The Overview for Agricultural Biotechnology Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 20202029

We at MarketResearch.biz will help your business by providing the latest market reports containing all the data required to capture opportunities while increasing effectiveness. The report on Agricultural Biotechnology Market has been prepared with the help of modern analytical techniques such as SWOT Analysis and PESTLE Analysis which not only covers the technical areas but also the political and ecological factors that are affecting the market. Our report will help by providing a calculated forecast so as to make business aware of incoming possible opportunities and or problems.

Leading Market players like KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. have been maintaining their position in the Global Agricultural Biotechnology market with the help of their up-to-date knowledge and readily available data to make an informed decision to effectively act on any opportunities that present itself.

***Access FREE PDF Sample Copy of the Report(Contains- Keyplayers, Growth Value, Segments, etc)! Click here***

Various classifications have been applied to the data to make it more readable to suit the eyes of a businessman. Following are some of the classifications provided in the report;

By Application:Vaccine DevelopmentTransgenic Crops and AnimalsAntibiotic DevelopmentNutritional SupplementsFlower CulturingBiofuels

By Organism Type:PlantsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesAnimalsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesMicrobesConventional TechniquesEstablished Genetic ModificationNew Breeding Techniques

Regional Analysis:

1. North America (United States, Canada)

2. Europe (Germany, Spain, France, UK, Russia, and Italy)

3. Asia-Pacific (China, Japan, India, Australia, and South Korea)

4. Latin America (Brazil, Mexico, etc.)

5. The Middle East and Africa (GCC and South Africa)

Available Array of Customizations:

Country-level bifurcation of data in terms of Type and Application for any specific country/countries.

Expansion of scope and data forecasts until 2029

Company Market Share for specific country/countries and regions

Customized Report Framework for Go-To-Market Strategy

Customized Report Framework for Merger & Acquisitions and Partnerships/JVs Feasibility

Customized Report Framework for New Product/Service Launch and/or Expansion

Any other Miscellaneous requirements with feasibility analysis

*****Any query?Inquire/Share Your Questions HereOr Report Customization*****

Which prime data figures are included in the report?

-Market size (Last few years, current and expected)

-Market share analysis as per different companies

-Market forecast

-Demand

-Price Analysis

-Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report?

-Market Investigators

-Teams, departments, and companies

-Competitive organizations

-Individual professionals

-Vendors, Buyers, Suppliers

What are the crucial aspects incorporated in the report?

-Industry Value Chain

-Consumption Data

-Market Size Expansion

-Key Economic Indicators

In this study, the years considered to estimate the market size of the Agricultural Biotechnology are as follows:

Base Year:2019 | Estimated Year:2020 | Forecast Year: 2020 to 2029

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

The report caters to the subsequent questions pertaining To the Agricultural Biotechnology market:

Which Regional market is very likely to witness the maximum growth in terms of talk and value?

What Are the latest trends in the sector that is Agricultural Biotechnology?

What Is the forecasted value of this Agricultural Biotechnology economy in 2019?

Which End-use is likely to gain significant traction?

How Have advancements impacted the production procedures of this Agricultural Biotechnology in the last several years?

Purposes Behind Buying Agricultural Biotechnology Report:-

-> This report gives a stick direct examination toward changing focused elements.

-> It gives a forward-looking perspective on changed elements producing or restricting business sector improvement.

-> It gives a five-year evaluation surveyed based on how the market is anticipated to develop.

-> It helps in understanding the essential part sections and their prospect.

-> It gives stick point investigation of changing competition components and keeps you in front of contenders.

-> It helps in settling on educated business decisions by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

The Agricultural Biotechnology Market report concludes with sharing vital report findings with readers. Here on the basis of the study of historical data, the examination of the current scenarios overserved in various markets including regional and domestic and trends recorded, it delivers a forecast of the market. This includes segmental forecast, market size forecast, regional market forecast, consumption forecast.

Why Pick Marketresearch.biz?

Systematic Market research procedure

Data Gathered from credible and dependable secondary and primary resources

Team Of highly trained and skilled analysts with a profound comprehension of the most recent market research methods

Swift and efficient ordering process

Round the clock customer support catering to inquiries from global and domestic Customers

TO Download Detailed TOC ofAgricultural Biotechnology Market@https://marketresearch.biz/report/agricultural-biotechnology-market/#toc

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Thanks a million for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest.

See the original post here:
Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - TheLoop21

Read More...

Page 36«..1020..35363738..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick